| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/06/1998 | US5705477 Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use |
| 01/06/1998 | US5705388 CETP Ribozymes |
| 01/06/1998 | US5705380 Identification of a gene encoding TULP2, a retina specific protein |
| 01/06/1998 | US5705377 Tyrosine kinase |
| 01/06/1998 | US5705364 Mammalian cell culture process |
| 01/06/1998 | US5705363 Recombinant production of human interferon τ polypeptides and nucleic acids |
| 01/06/1998 | US5705361 Hybrid transposon with PT operon, plasmids and bacterial strains therefor |
| 01/06/1998 | US5705360 Chemokine N-terminal deletion mutations |
| 01/06/1998 | US5705355 Having specified amino acid sequence; diagnosis of clot formation and separation of clotting factor |
| 01/06/1998 | US5705342 Interaction of BCL-2 and R-RAS |
| 01/06/1998 | US5705334 Uses for DNA structure-specific recognition protein |
| 01/06/1998 | US5705197 Extraction process for producing PLGA microspheres |
| 01/06/1998 | US5705178 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
| 01/06/1998 | US5705177 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
| 01/06/1998 | US5705163 Target-specific, cytotoxic, recombinant pseudomonas exotoxin |
| 01/06/1998 | US5705159 Immunoreactive peptide sequence from a 43 KD human cancer antigen |
| 01/06/1998 | US5705157 Methods of treating cancerous cells with anti-receptor antibodies |
| 01/06/1998 | US5705156 Pseudomonas exotoxins binding to cells |
| 01/06/1998 | US5705153 Glucocerebrosidase conjugate and polyoxyalkylene oxide strands |
| 01/06/1998 | US5705149 Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors |
| 01/06/1998 | US5705143 Biological targeting agents |
| 01/06/1998 | US5704910 Implantable device and use therefor |
| 01/06/1998 | CA2033814C Inhibitor of the proliferation of herpesviruses and inhibitor of the recurrence of affections caused by their latent infection |
| 01/06/1998 | CA1339623C Lhrh antagonists |
| 01/02/1998 | DE19624426A1 Magnetic particle for transport of diagnostic or therapeutic agent |
| 01/02/1998 | DE19622502A1 Truncated versions of exendin peptide(s) for treating diabetes |
| 01/01/1998 | CA2205543A1 Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
| 12/31/1997 | WO1997049832A2 Method of identifying cytochrome p450 |
| 12/31/1997 | WO1997049828A1 Novel tata-box binding protein-associated factors essential for yeast viability |
| 12/31/1997 | WO1997049827A2 Adenoviral mediated gene transfer in adipocytes and related implants |
| 12/31/1997 | WO1997049818A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 12/31/1997 | WO1997049817A1 Brain glycogen phosphorylase cancer antigen |
| 12/31/1997 | WO1997049815A1 Retinoid metabolizing protein |
| 12/31/1997 | WO1997049809A1 Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use |
| 12/31/1997 | WO1997049808A1 The caip-like gene family |
| 12/31/1997 | WO1997049807A2 A NOVEL HYPERTENSION RELATED CALCIUM REGULATED GENE (HCaRG) |
| 12/31/1997 | WO1997049805A2 Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| 12/31/1997 | WO1997049801A1 Process for producing prothrombin as a basic antidote substance for natural and synthetic thrombin inhibitors |
| 12/31/1997 | WO1997049800A1 Anti-cocaine catalytic antibody |
| 12/31/1997 | WO1997049798A1 Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth, and of enteric innervation |
| 12/31/1997 | WO1997049732A1 IgG IMMUNOGLOBULINS AND F(ab')2 FRAGMENTS THEREOF, SPECIFIC FOR DRUGS AND METABOLITES THEREOF, AND THEIR USE FOR DETOXIFICATION PURPOSES |
| 12/31/1997 | WO1997049731A1 Cell adhesion inhibiting compounds |
| 12/31/1997 | WO1997049729A1 Polypeptides mimicking the activity of human erythropoietin |
| 12/31/1997 | WO1997049726A1 Recombinant ribosomal inhibitor protein (rip) and use as immunoconjugate |
| 12/31/1997 | WO1997049725A1 Modified factor viii |
| 12/31/1997 | WO1997049724A1 Cyclic depsipeptides and drugs containing the same as the active ingredient |
| 12/31/1997 | WO1997049723A1 Cationic lipids for delivery of nucleic acid to cells |
| 12/31/1997 | WO1997049722A1 Depsipeptides and drugs containing the same as the active ingredient |
| 12/31/1997 | WO1997049721A1 Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin |
| 12/31/1997 | WO1997049432A1 Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
| 12/31/1997 | WO1997049430A1 Immunotherapy by modulation of antigen presentation |
| 12/31/1997 | WO1997049429A1 Genetically engineered immunoglobulins with specificity for glycated albumin |
| 12/31/1997 | WO1997049428A1 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 12/31/1997 | WO1997049427A1 Drugs for ameliorating renal disorders |
| 12/31/1997 | WO1997049426A1 Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient |
| 12/31/1997 | WO1997049424A1 Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
| 12/31/1997 | WO1997049423A2 Liposomal influenza vaccine composition and method |
| 12/31/1997 | WO1997049422A1 Method of using ligands of the kappa opioid receptor |
| 12/31/1997 | WO1997049421A1 Gm-csf administration for the treatment and prevention of recurrence of brain tumors |
| 12/31/1997 | WO1997049420A1 Lectin compositions and uses thereof |
| 12/31/1997 | WO1997049419A1 Ophthalmic drug compositions |
| 12/31/1997 | WO1997049418A1 Methods of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
| 12/31/1997 | WO1997049417A1 Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof |
| 12/31/1997 | WO1997049414A1 Manufacturing process for the production of purified transferrin |
| 12/31/1997 | WO1997049404A1 Anticoagulant agents |
| 12/31/1997 | WO1997049392A1 A composition of enalapril and losartan |
| 12/31/1997 | WO1997049386A1 Oral delivery of peptides |
| 12/31/1997 | WO1997049373A2 Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin |
| 12/31/1997 | WO1997045528A3 Mammalian tolloid-like gene and protein |
| 12/31/1997 | WO1997044454A3 Human phospholipase inhibitor |
| 12/31/1997 | WO1997041226A3 Polynucleotides encoding the transcriptional repressor gcf2 of the epidermal growth factor receptor |
| 12/31/1997 | WO1997035880A3 Polynucleic acid sequences that are functionally associated with the development of autoimmune disease |
| 12/31/1997 | WO1997035873A3 Peptides with antiproliferative properties |
| 12/31/1997 | CN1169158A Analogs of acidic fibroblast growth factor having enhanced stability and biological activity |
| 12/31/1997 | CN1036837C Method for preparing nutrition composition for mammals |
| 12/31/1997 | CA2259228A1 Adenoviral mediated gene transfer in adipocytes and related implants |
| 12/31/1997 | CA2259159A1 Depsipeptides and drugs containing the same as the active ingredient |
| 12/31/1997 | CA2259124A1 Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof |
| 12/31/1997 | CA2258915A1 Anticoagulant agents |
| 12/31/1997 | CA2258871A1 Polypeptides mimicking the activity of human erythropoietin |
| 12/31/1997 | CA2258608A1 Gm-csf administration for the treatment and prevention of recurrence of brain tumors |
| 12/31/1997 | CA2258564A1 Brain glycogen phosphorylase cancer antigen |
| 12/31/1997 | CA2258496A1 Anti-cocaine catalytic antibody |
| 12/31/1997 | CA2258487A1 Cyclic depsipeptides and drugs containing the same as the active ingredient |
| 12/31/1997 | CA2257946A1 A composition of enalapril and losartan |
| 12/31/1997 | CA2257180A1 Method of identifying cytochrome p450 |
| 12/31/1997 | CA2254995A1 Cell adhesion inhibiting compounds |
| 12/31/1997 | CA2254782A1 Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient |
| 12/31/1997 | CA2230088A1 A novel hypertension related calcium regulated gene (hcarg) |
| 12/30/1997 | USRE35706 Administering as viricides and antitumor agents |
| 12/30/1997 | US5703241 Inhibitor of farnesyl-protein transferase |
| 12/30/1997 | US5703220 May be used to provide therapeutic vehicles for treatment of processes involving function of melanocortin receptors |
| 12/30/1997 | US5703213 Monoclonal antibodies which recognize an adenocarcinoma cell antigen |
| 12/30/1997 | US5703212 Preventive for circulatory diseases |
| 12/30/1997 | US5703208 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors |
| 12/30/1997 | US5703206 Macrophage inflammatory protein 2 (MIP-2) |
| 12/30/1997 | US5703205 Laminin a chain polypeptides from the amino terminal golbular domain |
| 12/30/1997 | US5703106 Treating various cardiovascular, urogenital, brain disorders |
| 12/30/1997 | US5703076 Retroviral protease inhibitors |
| 12/30/1997 | US5703073 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |